

Company News

January 21, 2000

Additional Indication for 'Onon Capsule' (pranlukast hydrate)

Ono Pharmaceutical Co., Ltd. announces today that its bronchial asthma remedy 'Onon Capsule' (pranlukast hydrate) was granted approval for an additional indication to treat allergic rhinitis on January 18, 2000.

'Onon Capsule' is a leukotriene receptor antagonist, which was approved for the first time in the world as a bronchial asthma remedy in 1995. Since its launch, it has been widely used for adult patients with bronchial asthma. Since it has been known that leukotriene is also deeply involved in allergic rhinitis conditions, Ono carried out its clinical studies on patients with allergic rhinitis. As a result, 'Onon Capsule' proved effective in ameliorating the blocked nose, runny nose and sneezing, and was granted approval for its additional indication on January 18, 2000. To ensure safe and proper use of this drug as ever, Ono will keep medical institutions informed of any update.